NCT02113696

Intake of Omega 3 in Morbidly Obese Patients

The Effect of ω-3 Polyunsaturated Fatty Acids (Eicosapentaenoic Acid and Docosahexanoic Acid) on Morbidly Obese Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: Pontificia Universidade Católica do Rio Grande do Sul · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Ingestion of capsules of omega 3 EPA and DHA, with 1.8 g of EPA and 1.2 g DHA for morbidly obese patients, will improve the inflammatory status? C-reactive protein? Weight?

Detailed description

Intake of EPA and DHA for the management of morbid obesity in capsules \- Reduction of inflammatory factors such as adipokines, glucose, C-reactive protein, cholesterol, weight, BMI. Will be 2 groups: cases and controls. The cases will intake of omega 3 capsules and placebo control.

Conditions

• Morbid Obesity

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Omega 3 intake, morbid obesity	Individuals of both sexes with ages between 18 and 65 years took 3g of omega 3, and 1.8g eicosapentaenoic acid (EPA) and 1.2g docosahexanoic acid (DHA) for 8 weeks.
DIETARY_SUPPLEMENT	Placebo Capsules	They received gelatin (colorless) capsules. A nutritional evaluation was performed, a 24-h recordatory was applied to verify macro and micronutrients intake, biochemical evaluation before and after the intervention. Macro and micronutrients were calculated using the Avanutri 2.0 system. Clinical history was verified through a questionnaire previously filled out by a physician.

Timeline

• Start date: 2014-05-01
• Primary completion: 2014-06-01
• Completion: 2014-07-01
• First posted: 2014-04-15
• Last updated: 2014-07-08